Company profile: Nectero Medical
1.1 - Company Overview
Company description
- Provider of a minimally invasive treatment to stabilize growth and prevent rupture of small to mid-sized abdominal aortic aneurysms through the Nectero EAST® System, which uses a dual-balloon catheter to deliver a stabilizer mixture to strengthen the aortic wall; includes the stAAAble Trial to evaluate safety and efficacy in patients with infrarenal abdominal aortic aneurysms.
Products and services
- StAAAble Trial: A clinical trial evaluating safety and efficacy of the Nectero EAST® System in patients with infrarenal abdominal aortic aneurysms (clinical)
- Nectero EAST® System: Minimally invasive treatment for small to mid-sized abdominal aortic aneurysms, using a dual-balloon catheter to deliver a stabilizer mixture that strengthens aortic wall to prevent rupture (catheter-based).
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Nectero Medical
Clada Medical
HQ: Ireland
Website
- Description: Provider of design, test, and manufacture of catheter balloons and catheters, supporting development from initial concept through to full manufacture.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Clada Medical company profile →
Aegerion Pharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical therapeutics to treat cardiovascular and metabolic diseases, focused on the development and commercialization of therapies, including lomitapide (AEGR-733), a microsomal triglyceride transfer protein inhibitor small molecule drug designed to decrease serum lipids.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aegerion Pharmaceuticals company profile →
Marea Therapeutics
HQ: United States
Website
- Description: Provider of biotechnology therapies leveraging human genetics to develop next-generation treatments for cardiometabolic diseases. Pipeline includes MAR001, a monoclonal antibody targeting ANGPTL4 to reduce remnant cholesterol and triglycerides and improve adipose tissue function (Phase 2), MAR002, an anti-growth hormone receptor antibody for acromegaly, and undisclosed discovery programs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Marea Therapeutics company profile →
Micell Technologies
HQ: United States
Website
- Description: Provider of biomedical device solutions focused on developing interventional cardiology systems for vascular drug delivery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Micell Technologies company profile →
Lombard Medical
HQ: United Kingdom
Website
- Description: Provider of minimally invasive endovascular stent graft systems for aortic aneurysm repair, developing, manufacturing and marketing solutions for EVAR and TEVAR. Products include Minos, Aorfix (for highly angulated aortic necks), Altura and Meridian (non-standard, named-patient) for EVAR, and Hercules and Castor (custom branched, named-patient) for thoracic cases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lombard Medical company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Nectero Medical
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Nectero Medical
2.2 - Growth funds investing in similar companies to Nectero Medical
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Nectero Medical
4.2 - Public trading comparable groups for Nectero Medical
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →